Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart rate drug may speed recovery from shock after heart attack

NCT ID NCT07714746

Disease control Sponsor: National Institute of Cardiovascular Diseases, Pakistan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This trial tests whether ivabradine, a drug that lowers heart rate, can help people recover from cardiogenic shock—a life-threatening condition where the heart can't pump enough blood—after a heart attack. Participants receive either ivabradine or a placebo for three days, and doctors track their recovery using a scoring system that measures blood pressure, oxygen levels, urine output, and other signs. The goal is to see if ivabradine leads to faster improvement and less need for strong heart-supporting medications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ivabradine, a drug that lowers heart rate
What this could lead to
If it works, ivabradine could offer a new way to help people recover from cardiogenic shock after a heart attack, potentially reducing the need for strong heart-support medications.
What could go wrong
This is a relatively small, early-phase trial, so results may not apply to all patients. Ivabradine can cause side effects like slow heart rate, irregular heartbeat, or low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18-75 years diagnosed with STEMI complicated by cardiogenic shock (CS) as defined by SCAI shock classification \> C: Signs of Hypoperfusion including: 1. SBP \<90 OR MAP \<60 OR \>30 mmHg drop from baseline AND drugs/device used to maintain BP above these targets 2. Cold, clammy extremities 3. Urine output \<30 mL/h 4. pulmonary congestion (either crackles, congestion in chest X-ray or B-lines in lung US) 5. Mixed venous oxygen saturation ≤ 65% * Severe Left ventricular (LV) dysfunction or right ventricular (RV) infarction * Heart rate (HR) ≥ 100 bpm (Sinus Rhythm) in whom beta-blocker therapy cannot be initiated, including: On inotropic or vasopressor support, Requiring an intra-aortic balloon pump (IABP), With Killip class III or IV, Requiring BiPAP or mechanical ventilation Exclusion Criteria: * Age \> 75 years * CPR \> 12 mints * Atrial fibrillation * Complete Heart Block * Heart rate of \< 100 bpm * End stage Renal Disease * Extensive comorbidities; Prior CVA, Malignancy, Pregnancy or Ongoing Participation in Other Trials

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiogenic shock post myocardial infarction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiogenic shock Shock, Cardiogenic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiogenic shock post myocardial infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National institute of cardiovascular diseases

    RECRUITING

    Karachi, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.